参考文献:1.中华医学会血液学分会白血病淋巴瘤学组.原发性骨髓纤维化诊断与治疗中国指南(2019年版)[J].中华血液学杂志, 2019, 40(1):7.DOI:10.3760/cma.j.issn.0253-2727.2019.01.001.2.Harrison CN, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017 Oct;96(10):1653-1665. doi: 10.1007/s00277-017-3082-y. Epub 2017 Aug 5.3.Guaraná M,et al. Myeloproliferative Neoplasm Symptom Assessment Form – Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese. Hematol Transfus Cell Ther. 2022 Jul-Sep;44(3):321-327. doi: 10.1016/j.htct.2020.10.966. Epub 2021 Jan 3.4.Passamonti F,et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.
5.Xu Z,et al. Unique features of primary myelofibrosis in Chinese. Blood. 2012 Mar 15;119(11):2469-73. doi: 10.1182/blood-2011-11-389866. Epub 2012 Jan 18.
7.Laman M, et al. Ultrasonographic assessment of splenic volume at presentation and after anti-malarial therapy in children with malarial anaemia. Malar J. 2015 May 28;14:219. doi: 10.1186/s12936-015-0741-0.
8.Tremblay D, Mesa R. Novel treatments for myelofibrosis: beyond JAK inhibitors. Int J Hematol. 2022 May;115(5):645-658. doi: 10.1007/s12185-022-03299-8. Epub 2022 Feb 19.
9.Bankar A, Gupta V. Investigational non-JAK inhibitors for chronic phase myelofibrosis. Expert Opin Investig Drugs. 2020May;29(5):461-474. doi: 10.1080/13543784.2020.1751121. Epub 2020 Apr 29.
10.Ferreira Gomes G, et al. Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis. Curr Hematol Malig Rep. 2023 Aug;18(4):113-120.